Page 24 - Read Online

Page 72 Bhasin et al. J Transl Genet Genom 2024;8:55-76 https://dx.doi.org/10.20517/jtgg.2023.46

killing. PLoS One 2017;12:e0183390. DOI PubMed PMC
35. Zarrabi KK, Narayan V, Mille PJ, et al. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Ther Adv Urol 2023;15:17562872231182219. DOI PubMed PMC
36. Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ. Redirecting T cells to eradicate B-cell acute lymphoblastic
leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia 2017;31:777-87. DOI PubMed
37. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with
antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-8. DOI PubMed PMC
38. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science
2018;359:1361-5. DOI
39. Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively
transferred tumor-specific T cells. J Immunother 2010;33:1-7. DOI PubMed PMC
40. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T
cells. Int J Mol Sci 2019;20:1283. DOI PubMed PMC
41. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood
2014;124:188-95. DOI
42. Van De Vyver AJ, Marrer-Berger E, Wang K, Lehr T, Walz AC. Cytokine release syndrome by T-cell-redirecting therapies:
can we predict and modulate patient risk? Clin Cancer Res 2021;27:6083-94. DOI PubMed
43. Maus MV, Alexander S, Bishop MR, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune
effector cell-related adverse events. J Immunother Cancer 2020;8:e001511. DOI PubMed PMC
44. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
Nat Rev Immunol 2022;22:85-96. DOI PubMed PMC
45. Klinger M, Zugmaier G, Nägele V, et al. Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic
adverse events. Cancer Res 2020;80:91-101. DOI
46. Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia
treated with blinatumomab: management and mitigating factors. Ann Hematol 2019;98:159-67. DOI PubMed PMC
47. Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat
Rev Clin Oncol 2023;20:49-62. DOI PubMed PMC
48. Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-
engineered T-cells-a completed study overview. Biochem Soc Trans 2016;44:951-9. DOI PubMed
49. Guo Y, Feng K, Liu Y, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced
biliary tract cancers. Clin Cancer Res 2018;24:1277-86. DOI
50. Feng K, Liu Y, Guo Y, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary
tract cancers and pancreatic cancers. Protein Cell 2018;9:838-47. DOI PubMed PMC
51. Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-
specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol
Immunother 2017;66:1425-36. DOI PubMed PMC
52. Kong HY, Byun J. Emerging roles of human prostatic acid phosphatase. Biomol Ther 2013;21:10-20. DOI PubMed PMC
53. Gunia S, Koch S, May M, Dietel M, Erbersdobler A. Expression of prostatic acid phosphatase (PSAP) in transurethral resection
specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows Arch
2009;454:573-9. DOI PubMed
54. Schaeffer EM, Srinivas S, Adra N, et al. NCCN guidelines® insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw
2022;20:1288-98. DOI PubMed
55. Madan RA, Antonarakis ES, Drake CG, et al. Putting the pieces together: completing the mechanism of action jigsaw for sipuleucel-
T. J Natl Cancer Inst 2020;112:562-73. DOI PubMed PMC
56. Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014;15:115-26.
DOI PubMed PMC
57. Schnell U, Cirulli V, Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta 2013;1828:1989-
2001. DOI PubMed
58. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712. DOI
59. Huang L, Yang Y, Yang F, et al. Functions of EpCAM in physiological processes and diseases (review). Int J Mol Med
2018;42:1771-85. DOI PubMed PMC
60. Zhou N, Wang H, Liu H, et al. MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung
cancer. J Exp Clin Cancer Res 2015;34:157. DOI PubMed PMC
61. Massoner P, Thomm T, Mack B, et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy
and modulated by MET-associated miRNA-200c/205. Br J Cancer 2014;111:955-64. DOI PubMed PMC
62. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to
epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-21. DOI PubMed PMC
63. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010;2:129-36. DOI PubMed PMC
64. Mau-Sørensen M, Dittrich C, Dienstmann R, et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody